CAR T-cell therapy (Poseida/Janssen Biotech)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug NameCAR T-cell therapy (Poseida/Janssen Biotech)
Drug Alias NameCAR T-cell therapy (Transposagen/Janssen Biotech)chimeric antigen receptor T-cell therapy (Transposagen/Janssen Biotech)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionImmunostimulantsT lymphocytes stimulants
TargetsUpdating
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesTransposagen Biopharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPoseida Therapeutics IncJanssen Biotech IncTransposagen Biopharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A